Buy Back or Pay Forward?
The pharmaceutical industry likes to argue that companies need to be guaranteed a robust return on investments if they are to invest in new treatments. And yet there is a good reason why drug firms should help solve the problem of antimicrobial resistance: enlightened self-interest.
https://prosyn.org/8s7MpZV
LONDON – When British Prime Minister David Cameron asked me to lead a review into the problem of antimicrobial resistance, the last thing I expected was that accepting the position would lead me to question one of the most popular tools for corporate financial management: share buybacks.